Beta-O2 Technologies Ltd. is a biomedical company, developing a proprietary implantable bio-artificial pancreas, the ßAir, for the treatment and potential cure of type 1 diabetes.
Beta-O2 develops patient-centric solutions to improve the health and quality of life of patients suffering from Type 1 Diabetes.
The βAir device contains living cells that sense the level of glucose and produce insulin and glucagon accordingly.
The βAir device provides the same functionality as the pancreas, therefore retaining glycemic control.
Free of Insulin Injections and glucose monitoring
βAir is an implantable device, eliminating the need for frequent insulin injections and glucose measurements.
No Immunosuppressive Therapy
The βAir device allows for immune-isolation of the implanted cells, thereby eliminating the need for immunosuppressive therapy.